Literature DB >> 17171588

Prevention of venous thromboembolism.

Mario Pini1, Alex C Spyropoulos.   

Abstract

Patients with clinical conditions such as surgery, trauma, and acute medical illness have a transiently increased risk of venous thromboembolism and merit consideration for adequate thromboprophylaxis. The choice of an appropriate pharmacologic or physical means of prophylaxis should be made taking into account both the thrombotic and bleeding risk associated with patient-related factors and the type of surgery or other disease state involved. A large number of randomized clinical trials, meta-analyses, and guidelines developed by scientific societies worldwide have addressed this issue and have provided information and recommendations that should be considered carefully. The aim of this review is to provide the practicing physician with a brief updated summary of the subject, stratifying those patients at low thrombotic risk who do not require specific thromboprophylaxis apart from early ambulation, from those at moderate or higher thrombotic risk. Patients at moderate thrombotic risk face a 10 to 20% risk of deep vein thrombosis (DVT) and require prophylaxis with low-dose unfractionated heparin or low molecular weight heparins (LMWHs) at a dosage < 3400 U once daily, or with graduated elastic stockings if their bleeding risk is high. Patients with an expected 20 to 40% DVT rate without prophylaxis are considered at high thrombotic risk and should be treated preferentially with LMWHs at high prophylactic dosage (> 3400 U). Patients undergoing major orthopedic surgery face a DVT rate > 40%, are considered at very high risk of venous thromboembolism, and should be given either LMWHs at high prophylactic dosage, fondaparinux, or vitamin K antagonists--either alone or in association with intermittent pneumatic compression devices.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17171588     DOI: 10.1055/s-2006-955458

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  5 in total

1.  Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations.

Authors:  Olav Reikerås; Torkil Clementsen
Journal:  J Thromb Thrombolysis       Date:  2008-12-06       Impact factor: 2.300

Review 2.  Epidemiology and risk factors for venous thrombosis.

Authors:  Mary Cushman
Journal:  Semin Hematol       Date:  2007-04       Impact factor: 3.851

3.  Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery.

Authors:  Elham Rahme; Kaberi Dasgupta; Mark Burman; Hongjun Yin; Sasha Bernatsky; Greg Berry; Hacene Nedjar; Susan R Kahn
Journal:  CMAJ       Date:  2008-06-03       Impact factor: 8.262

4.  Underutilization of pharmacological thromboprophylaxis in obstetrics and gynaecology patients in the absence of a risk assessment tool.

Authors:  Galila F Zaher
Journal:  J Taibah Univ Med Sci       Date:  2017-09-15

5.  Deep Vein Thrombosis and Pulmonary Embolism in Liver Transplant Patients: Risks and Prevention.

Authors:  James Yip; David A Bruno; Charlotte Burmeister; Marwan Kazimi; Atsushi Yoshida; Marwan S Abouljoud; Gabriel T Schnickel
Journal:  Transplant Direct       Date:  2016-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.